These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 30481878)
21. Primary prophylaxis of overt hepatic encephalopathy in patients with cirrhosis: an open labeled randomized controlled trial of lactulose versus no lactulose. Sharma P; Sharma BC; Agrawal A; Sarin SK J Gastroenterol Hepatol; 2012 Aug; 27(8):1329-35. PubMed ID: 22606978 [TBL] [Abstract][Full Text] [Related]
22. [Hepatic encephalopathy and liver transplantation]. Fehérvári I; Nemes B; Görög D; Gerlei Z; Kóbori L Magy Seb; 2012 Apr; 65(2):58-62. PubMed ID: 22512880 [TBL] [Abstract][Full Text] [Related]
24. Hepatic encephalopathy: Diagnosis and management. Amodio P Liver Int; 2018 Jun; 38(6):966-975. PubMed ID: 29624860 [TBL] [Abstract][Full Text] [Related]
25. Review article: the modern management of hepatic encephalopathy. Bajaj JS Aliment Pharmacol Ther; 2010 Mar; 31(5):537-47. PubMed ID: 20002027 [TBL] [Abstract][Full Text] [Related]
26. Efficacy of Rifaximin in prevention of recurrence of hepatic encephalopathy in patients with cirrhosis of liver. Ali B; Zaidi YA; Alam A; Anjum HS J Coll Physicians Surg Pak; 2014 Apr; 24(4):269-73. PubMed ID: 24709242 [TBL] [Abstract][Full Text] [Related]
27. Update on the Therapeutic Management of Hepatic Encephalopathy. Kornerup LS; Gluud LL; Vilstrup H; Dam G Curr Gastroenterol Rep; 2018 Apr; 20(5):21. PubMed ID: 29644492 [TBL] [Abstract][Full Text] [Related]
28. Durability of rifaximin response in hepatic encephalopathy. Neff GW; Jones M; Broda T; Jonas M; Ravi R; Novick D; Kaiser TE; Kemmer N J Clin Gastroenterol; 2012 Feb; 46(2):168-71. PubMed ID: 22011586 [TBL] [Abstract][Full Text] [Related]
30. [Role of rifaximin in the treatment of hepatic encephalopathy]. Sanchez-Delgado J; Miquel M Gastroenterol Hepatol; 2016 Apr; 39(4):282-92. PubMed ID: 26545947 [TBL] [Abstract][Full Text] [Related]
31. Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled study. Sanyal A; Younossi ZM; Bass NM; Mullen KD; Poordad F; Brown RS; Vemuru RP; Mazen Jamal M; Huang S; Merchant K; Bortey E; Forbes WP Aliment Pharmacol Ther; 2011 Oct; 34(8):853-61. PubMed ID: 21848797 [TBL] [Abstract][Full Text] [Related]
32. [Clinical importance and diagnostic methods of minimal hepatic encephalopathy]. Stawicka A; Zbrzeźniak J; Świderska A; Kilisińska N; Świderska M; Jaroszewicz J; Flisiak R Pol Merkur Lekarski; 2016 Feb; 40(236):117-21. PubMed ID: 27000818 [TBL] [Abstract][Full Text] [Related]
33. Role of circadian rhythm and autonomic nervous system in liver function: a hypothetical basis for improving the management of hepatic encephalopathy. Ishay Y; Kolben Y; Kessler A; Ilan Y Am J Physiol Gastrointest Liver Physiol; 2021 Oct; 321(4):G400-G412. PubMed ID: 34346773 [TBL] [Abstract][Full Text] [Related]
34. Rifaximin for the treatment of hepatic encephalopathy. Mullen K; Prakash R Expert Rev Gastroenterol Hepatol; 2010 Dec; 4(6):665-77. PubMed ID: 21108586 [TBL] [Abstract][Full Text] [Related]
35. Hepatic encephalopathy: pathophysiology and emerging therapies. Sundaram V; Shaikh OS Med Clin North Am; 2009 Jul; 93(4):819-36, vii. PubMed ID: 19577116 [TBL] [Abstract][Full Text] [Related]
36. Gut flora and hepatic encephalopathy in patients with cirrhosis. Riordan SM; Williams R N Engl J Med; 2010 Mar; 362(12):1140-2. PubMed ID: 20335591 [No Abstract] [Full Text] [Related]
37. Current state of knowledge of hepatic encephalopathy (part III): non-absorbable disaccharides. Morgan MY Metab Brain Dis; 2016 Dec; 31(6):1361-1364. PubMed ID: 27638474 [TBL] [Abstract][Full Text] [Related]
38. Bispectral index monitoring for diagnosis and assessment of severity of hepatic encephalopathy in cirrhotic patients. Jindal A; Sharma BC; Sachdeva S; Chawla R; Srivastava S; Maharshi S Dig Liver Dis; 2015 Sep; 47(9):769-74. PubMed ID: 26022229 [TBL] [Abstract][Full Text] [Related]
39. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy. Agrawal A; Sharma BC; Sharma P; Sarin SK Am J Gastroenterol; 2012 Jul; 107(7):1043-50. PubMed ID: 22710579 [TBL] [Abstract][Full Text] [Related]
40. Hepatic encephalopathy: nomenclature, pathogenesis and treatment. Quero Guillén JC; Carmona Soria I; García Montes JM; Jiménez Sáenz M; Herrerías Gutiérrez JM Rev Esp Enferm Dig; 2003 Feb; 95(2):135-42, 127-34. PubMed ID: 12760720 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]